Finward Bancorp’s AstraZeneca AZN Stock Holding History

Finward Bancorp’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$250K	Hold	1,548	–	–	0.18%	91
2026 Q2	$294K	Hold	1,548	–	–	0.22%	84
2026 Q1	$305K	Sell	1,548 -1	-0.1%	-$193	0.24%	81
2025 Q4	$285K	Hold	1,549	–	–	0.22%	83
2025 Q3	$238K	Hold	1,549	–	–	0.18%	97
2025 Q2	$216K	Hold	1,549	–	–	0.17%	95
2025 Q1	$228K	Buy	+1,549	New	+$224K	0.2%	93

Other funds holding AZN

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $103B AUM 36.66% 1-Year Est. Return

SEB Asset Management Stockholm $27B AUM

M&G plc London, United Kingdom $19.9B AUM 15.09% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Parnassus Investments San Francisco, California $33.8B AUM 31.08% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Finward Bancorp's AZN Position: Q3 2026 in Review

Finward Bancorp held its AstraZeneca (AZN) position steady in Q3 2026 at 1,548 shares worth $250K. The position accounts for 0.18% of the portfolio, ranked #91.

Finward Bancorp first reported a position in AZN in Q1 2025 and has held it in 7 quarters since. The position peaked at $305K in Q1 2026. 736 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

Finward Bancorp held 1,548 shares of AstraZeneca worth $250K as of Q3 2026.
Finward Bancorp left its AstraZeneca share count unchanged in Q3 2026.
AstraZeneca made up 0.18% of Finward Bancorp's portfolio in Q3 2026, its #91 holding.
Finward Bancorp first reported a position in AstraZeneca in Q1 2025 and has held it in 7 quarters since.
Finward Bancorp's AstraZeneca position peaked at $305K in Q1 2026.
736 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Finward Bancorp's 13F filing for Q3 2026, filed 14 Oct 2026.